Nerviano Medical Sciences S.r.l. to Present New Preclinical Data for NMS-812 and NMS-0963 at the American Association for Cancer Research (AACR) 2023 Annual Meeting
NMS-812: A potent and selective PERK/GCN2 inhibitor, a potential first-in-class targeting the ISR entered FIH clinical trial mid-2022
NMS-0963: A selective and orally available Syk inhibitor with promising preclinical activity in diffuse large B-cell lymphoma
Nerviano, 05 April 2023 – Nerviano Medical Sciences Srl,a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, today announced that two posters will be presented at the upcoming AACR annual meeting which will be held April 14-19, 2023 at the Orange County Convention Center, Orlando, Florida.
Poster #: 1615. Title: NMS-812, a novel potent PERK inhibitor that also inhibits GCN2, exhibits strong anti-tumor activity as single agent and in combination in preclinical models. Presenter: Claudia Perrera, PhD, Head of Discovery Pharmacology, Nerviano Medical Sciences. Session: PO.ET09.03 – Novel Antitumor Agents 3. When: Monday, April 17 9.00 AM-12.30 PM ET. Where: Section 17 of the Exhibition Hall.
Poster #: 4036. Title: NMS-0963 is a novel potent, selective and orally available Syk inhibitor with promising preclinical activity in diffuse large B-cell lymphoma. Presenter: Grazia Saturno, PhD, Global Asset Leader, Nerviano Medical Sciences. Session: PO.ET09.08 – Tyrosine Kinase and Phosphatase Inhibitors 2. When: Tuesday, April 18 9.00 AM-12.30 PM ET. Where: Section 21 of the Exhibition Hall.
* * * * * * * *
About NMS-812
NMS-812 is a potent and selective inhibitor of PERK and GCN2, two key kinases involved in regulating the “integrated stress response” (ISR), a series of signaling pathways that facilitate cellular adaptation to various types of stress conditions and which, importantly, include those commonly encountered by tumor cells. In this presentation, we elucidate key preclinical data which led to selection of NMS-812 as a clinical candidate. NMS-812 has the potential to be a first-in-class agent targeting the ISR and started patient enrolment in a FIH clinical trial in the setting of relapsed/refractory multiple myeloma in mid-2022 (NCT05027594).
About NMS-0963
NMS-0963 is a novel potent, selective and orally available Syk (Spleen tyrosine kinase) inhibitor. Syk is a non-receptor cytoplasmic tyrosine kinase that plays a fundamental role in BCR (B-Cell Receptor) signaling. Syk represents a therapeutic target for the inhibition of the BCR pathway in B-Cell malignancies, such as Diffuse Large B-Cell Lymphoma (DLBCL), which depend on BCR signaling for aberrant proliferation and growth. In this poster, we present the discovery and characterization of NMS-0963 including in vitro biochemical profile, cell proliferation/mechanism of action and in vivo pharmacodynamic and efficacy data which support the rationale for clinical development of NMS-0963 in DLBCL.
Link:20230404-PERK and SYK posters AACR2023_PressRelease
from NMSGroup
